• 1
    Fraenkel L, Zhang Y, Chaisson CE, Maricq HR, Evans SR, Brand F, et al. Different factors influencing the expression of Raynaud's phenomenon in men and women. Arthritis Rheum 1999; 42: 30610.
  • 2
    Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001; 357: 20428.
  • 3
    Hummers LK, Wigley FM. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 2003; 29: 293313.
  • 4
    Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al, for the Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46: 241020.
  • 5
    Franks AG. Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. Lancet 1982; 1: 767.
  • 6
    Fischer M, Reinhold B, Falck H, Torok M, Alexander K. Topical nitroglycerin ointment in Raynaud's phenomenon. Z Kardiol 1985; 74: 298302.
  • 7
    Anderson ME, Moore TL, Hollis S, Jayson MI, King TA, Herrick AL. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology (Oxford) 2002; 41: 3248.
  • 8
    Peterson LL, Vorhies C. Raynaud's syndrome: treatment with sublingual administration of nitroglycerin, swinging arm maneuver, and biofeedback training. Arch Dermatol 1983; 119: 3969.
  • 9
    Natsuda H, Shibui Y, Yuhara T, Akama T, Suzuki H, Yamane K, et al. Nitroglycerin tape for Raynaud's phenomenon of rheumatic disease patients: an evaluation of skin temperature by thermography. Ryumachi 1994; 34: 84953. In Japanese.
  • 10
    Kan C, Akimoto S, Abe M, Okada K, Ishikawa O. Preliminary thermographic evaluation of new nitroglycerine tape on the peripheral circulatory disturbance in systemic sclerosis. Ann Rheum Dis 2002; 61: 1779.
  • 11
    Teh LS, Manning J, Moore T, Tully MP, O'Reilly D, Jayson MI. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol 1995; 34: 63641.
  • 12
    Hummers LK, Dugowson CE, Dechow FJ, Wise RA, Bartolucci A, Wigley FM. A multi-center, blinded, randomized, placebo-controlled study of MQX-503, a topical gel formulation of nitroglycerin, in patients with Raynaud phenomenon (RP) [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S523.
  • 13
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 14
    Kleckner M Jr, Allen EV, Wakim KG. The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud's disease and Raynaud's phenomenon: studies on blood flow and clinical manifestations. Circulation 1951; 3: 6819.
  • 15
    Khan F, Greig IR, Newton DJ, Butler AR, Belch JJ. Skin blood flow after transdermal S-nitrosothio-acetylglucose. Lancet 1997; 350: 4101.
  • 16
    Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44: 18417.
  • 17
    Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford) 2005; 44: 14550.
  • 18
    Surwit RS, Gilgor RS, Allen LM, Duvic M. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma. Arch Dermatol 1984; 120: 32931.
  • 19
    Russell IJ, Lessard JA. Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study. J Rheumatol 1985; 12: 948.
  • 20
    Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001; 40: 103843.
  • 21
    Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient compliance with paper and electronic diaries. Control Clin Trials 2003; 24: 18299.
  • 22
    Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994; 120: 199206.
  • 23
    Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998; 41: 6707.
  • 24
    Caglayan E, Huntgeburth M, Karasch T, Weihrauch J, Hunzelmann N, Krieg T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 2006; 166: 2313.
  • 25
    Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005; 112: 29805.
  • 26
    Friedman EA, Harris PA, Wood AJ, Stein CM, Kurnik D. The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon. Clin Pharmacol Ther 2007; 81: 5039.
  • 27
    Schiopu E, Hsu VM, Impens AJ, Guerriere-Rothman JA, McCloskey DA, Seibold JR. Controlled trial of tadalafil in Raynaud phenomenon (RP) secondary to systemic sclerosis (SSc) [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S523.
  • 28
    Lauretti GR, Perez MV, Reis MP, Pereira NL. Double-blind evaluation of transdermal nitroglycerine as adjuvant to oral morphine for cancer pain management. J Clin Anesth 2002; 14: 836.
  • 29
    Watson HR, Robb R, Belcher G, Belch JJ. Seasonal variation of Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 1999; 26: 17347.
  • 30
    Gardner-Medwin JM, Macdonald IA, Taylor JY, Riley PH, Powell RJ. Seasonal differences in finger skin temperature and microvascular blood flow in healthy men and women are exaggerated in women with primary Raynaud's phenomenon. Br J Clin Pharmacol 2001; 52: 1723.